Danaher Corporation (NYSE:DHR) Shares Acquired by Puzo Michael J

Puzo Michael J lifted its holdings in Danaher Corporation (NYSE:DHR) by 4.9% in the first quarter, Holdings Channel reports. The firm owned 47,507 shares of the conglomerate’s stock after buying an additional 2,205 shares during the period. Danaher comprises about 2.8% of Puzo Michael J’s portfolio, making the stock its 17th largest position. Puzo Michael J’s holdings in Danaher were worth $9,739,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Fortis Capital Advisors LLC lifted its stake in shares of Danaher by 1.3% during the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate’s stock worth $914,000 after buying an additional 50 shares during the period. Fayez Sarofim & Co raised its position in shares of Danaher by 0.6% in the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate’s stock worth $1,902,000 after acquiring an additional 50 shares during the period. Coastal Bridge Advisors LLC boosted its position in Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate’s stock worth $252,000 after purchasing an additional 50 shares in the last quarter. Perennial Investment Advisors LLC lifted its position in shares of Danaher by 2.2% during the 4th quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate’s stock valued at $538,000 after buying an additional 51 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC grew its position in shares of Danaher by 3.1% in the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate’s stock valued at $399,000 after purchasing an additional 52 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DHR. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a research note on Monday, June 9th. Wolfe Research lowered their price objective on Danaher from $275.00 to $220.00 and set an “outperform” rating for the company in a research report on Monday, April 7th. Barclays raised their target price on Danaher from $205.00 to $215.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 22nd. The Goldman Sachs Group decreased their price target on Danaher from $260.00 to $240.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 23rd. Finally, Jefferies Financial Group cut their price objective on Danaher from $260.00 to $230.00 and set a “buy” rating for the company in a research report on Tuesday, April 22nd. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average price target of $248.17.

Danaher Trading Down 2.6%

DHR opened at $195.81 on Wednesday. The company has a market cap of $140.13 billion, a P/E ratio of 38.02, a PEG ratio of 2.82 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. Danaher Corporation has a one year low of $171.00 and a one year high of $281.70. The business’s 50-day simple moving average is $193.42 and its 200-day simple moving average is $210.43.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. As a group, equities research analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.65%. Danaher’s payout ratio is currently 24.85%.

Insider Activity at Danaher

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the firm’s stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president now owns 15,179 shares of the company’s stock, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the company’s stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman now directly owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.20% of the stock is owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.